CDKN2A and meningioma: As such, these results suggest that p16 immunohistochemistry can act as a cost- and time-effective prospective screen of CDKN2A gene status in the context of histologically higher grade meningiomas, with loss of p16 expression prompting additional molecular testing to confirm CDKN2A mutation or deletion.